Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Carlsmed (CARL) Cost of Revenue (2024 - 2026)

Carlsmed filings provide 2 years of Cost of Revenue readings, the most recent being -$19.6 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 1925.58% to -$19.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.0 million, a N/A change, with the full-year FY2025 number at $4.7 million, changed 0.37% from a year prior.
  • Cost of Revenue hit -$19.6 million in Q4 2025 for Carlsmed, down from $9.6 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $9.6 million in Q3 2025 to a low of -$19.6 million in Q4 2025.